Abstract
Viral hepatitis affects millions of people worldwide, making it one of the most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection. Lamivudine can achieve a 3- to 4-log reduction in serum viral levels in patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50% of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three times weekly. In patients with chronic hepatitis C infection, the most effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.
| Original language | English |
|---|---|
| Pages (from-to) | 330-333 |
| Number of pages | 4 |
| Journal | Current Opinion in Gastroenterology |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 1 2002 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
Cite this
Viral hepatitis. / Marrero, Ricardo; Schiff, Eugene R.
In: Current Opinion in Gastroenterology, Vol. 18, No. 3, 01.01.2002, p. 330-333.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Viral hepatitis
AU - Marrero, Ricardo
AU - Schiff, Eugene R
PY - 2002/1/1
Y1 - 2002/1/1
N2 - Viral hepatitis affects millions of people worldwide, making it one of the most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection. Lamivudine can achieve a 3- to 4-log reduction in serum viral levels in patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50% of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three times weekly. In patients with chronic hepatitis C infection, the most effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.
AB - Viral hepatitis affects millions of people worldwide, making it one of the most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection. Lamivudine can achieve a 3- to 4-log reduction in serum viral levels in patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50% of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three times weekly. In patients with chronic hepatitis C infection, the most effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.
UR - http://www.scopus.com/inward/record.url?scp=0036226708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036226708&partnerID=8YFLogxK
U2 - 10.1097/00001574-200205000-00006
DO - 10.1097/00001574-200205000-00006
M3 - Article
C2 - 17033303
AN - SCOPUS:0036226708
VL - 18
SP - 330
EP - 333
JO - Current Opinion in Gastroenterology
JF - Current Opinion in Gastroenterology
SN - 0267-1379
IS - 3
ER -